Sukmo Kang, DVM;PhD

Cheongju-si, Korea, Republic of
Sukmo Kang, D.V.M., Ph.D. graduated from Seoul National University and received his doctorate in KAIST (Korean Advanced Institute of Science and Technology). He is majored in nanotech-based vaccine engineering and developed new strategies for delivering vaccine antigens and adjuvants.
Since he joined Biotoxtech groups, he has given consults for non-clinical development of new modality drugs and DDS technology-applied drugs. He has hold the director position of Biotoxtech, Keyfronbio and Keyprime research and is in charge of overall research planning and business development of BTT groups.
Speaking In
4:45 PM - 5:00 PM (PDT)
Monday, June 13
BTT Groups, head-quartered in Korea, are the global non-clinical service providers composed of…